Mmbg Investment Advisors CO. Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Mmbg Investment Advisors CO. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel reports. The firm purchased 14,105 shares of the medical research company’s stock, valued at approximately $7,078,000.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC raised its position in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $170,000. Raymond James Financial Inc. increased its holdings in shares of Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Royal Bank Of Canada upped their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Finally, Barclays increased their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $614.32 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company’s 50 day simple moving average is $536.26 and its 200 day simple moving average is $508.51. The company has a market capitalization of $227.14 billion, a price-to-earnings ratio of 33.05, a PEG ratio of 2.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the firm posted $4.28 EPS. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.